SUTTON, LA., A. HADZIDIMITRIOU, P. BALIAKAS, A. AGATHANGELIDIS, A. LANGERAK, S. STILGENBAUER, Šárka POSPÍŠILOVÁ, Z. DAVIS, F. FORCONI, F. DAVI, P. GHIA, R. ROSENQUIST and K. STAMATOPOULOS. Immunoglobulin genes in chronic lymphocytic leukemia: key to understanding the disease and improving risk stratification. Haematologica/the hematology journal. Fondazione Ferrata Storti, 2017, vol. 102, No 6, p. 968-971, 5 pp. ISSN 0390-6078. Available from: https://dx.doi.org/10.3324/haematol.2017.165605. |
Other formats:
BibTeX
LaTeX
RIS
@article{1388212, author = {Sutton, LA. and Hadzidimitriou, A. and Baliakas, P. and Agathangelidis, A. and Langerak, A. and Stilgenbauer, S. and Pospíšilová, Šárka and Davis, Z. and Forconi, F. and Davi, F. and Ghia, P. and Rosenquist, R. and Stamatopoulos, K.}, article_number = {6}, doi = {http://dx.doi.org/10.3324/haematol.2017.165605}, keywords = {CLL; immunoglobulin; B-cell}, language = {eng}, issn = {0390-6078}, journal = {Haematologica/the hematology journal}, title = {Immunoglobulin genes in chronic lymphocytic leukemia: key to understanding the disease and improving risk stratification}, volume = {102}, year = {2017} }
TY - JOUR ID - 1388212 AU - Sutton, LA. - Hadzidimitriou, A. - Baliakas, P. - Agathangelidis, A. - Langerak, A. - Stilgenbauer, S. - Pospíšilová, Šárka - Davis, Z. - Forconi, F. - Davi, F. - Ghia, P. - Rosenquist, R. - Stamatopoulos, K. PY - 2017 TI - Immunoglobulin genes in chronic lymphocytic leukemia: key to understanding the disease and improving risk stratification JF - Haematologica/the hematology journal VL - 102 IS - 6 SP - 968-971 EP - 968-971 PB - Fondazione Ferrata Storti SN - 03906078 KW - CLL KW - immunoglobulin KW - B-cell N2 - While triggering through the B-cell receptor (BcR) facilitates B-cell development and maintenance, it also carries intertwined risks for the emergence of lymphoid malignancies, since malignant B cells can exploit BcR signaling pathways in order to initiate and fuel clonal expansion. Indeed, substantial research into chronic lymphocytic leukemia (CLL), largely based on immunogenetic data, supports the notion that the clonotypic BcR immunoglobulin (IG) engages in the recognition of and selection by putative (auto)antigen.1 This highlights the critical role of the BcR IG in the pathophysiology of CLL and implies that disease development is functionally driven and dynamic, rather than being a simple stochastic process. From a clinical perspective, the remarkable therapeutic efficacy of novel drugs such as ibrutinib and idelalisib which target effectors of the BcR signaling pathway (BTK and PI3K™, respectively), further vouch for this idea, and herald a major paradigm shift which may ultimately lead to changes in the natural history of the disease ER -
SUTTON, LA., A. HADZIDIMITRIOU, P. BALIAKAS, A. AGATHANGELIDIS, A. LANGERAK, S. STILGENBAUER, Šárka POSPÍŠILOVÁ, Z. DAVIS, F. FORCONI, F. DAVI, P. GHIA, R. ROSENQUIST and K. STAMATOPOULOS. Immunoglobulin genes in chronic lymphocytic leukemia: key to understanding the disease and improving risk stratification. \textit{Haematologica/the hematology journal}. Fondazione Ferrata Storti, 2017, vol.~102, No~6, p.~968-971, 5 pp. ISSN~0390-6078. Available from: https://dx.doi.org/10.3324/haematol.2017.165605.
|